Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.18
Previous CloseN/A
Volume14.00K
Average Volume (3M)49.57K
Market Cap
AU$7.52M
Enterprise ValueAU$2.92M
Total Cash (Recent Filing)AU$5.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Business ModelA clear, clinical-stage R&D focus around neurological therapies and a defined lead program (IIH) creates a concentrated development pathway. This specialization supports efficient capital allocation, clear regulatory milestones, and value inflection points tied to trial and approval outcomes over months.
Debt-free Balance SheetZero debt materially reduces financial risk and interest burden, preserving flexibility to fund clinical programs via equity or partnerships. For a cash-burning biotech, debt-free status lengthens optionality and lowers default risk, a durable structural strength for the next several months.
Improving Loss And Cash Outflow TrendsYear-on-year narrowing of losses and reduced cash outflow signals improving operational discipline and efficiency. If sustained, this trend can extend runway and reduce near-term financing needs, supporting continuity of clinical programs and strategic optionality over the medium term.
Bears Say
Severe Revenue DeclineAn ~81% YoY revenue drop highlights volatility and limited commercial receipts, leaving the company reliant on external funding and clinical milestones for value creation. Small, inconsistent revenue undermines any near-term path to self-sustaining operations and exacerbates financing dependency.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow indicate ongoing cash burn that requires recurring capital raises or partnerships. This structural cash deficit increases dilution and can constrain R&D progress if capital markets or partner options tighten over the coming months.
Ongoing Losses And Declining EquitySustained operating and net losses have eroded equity and produced negative ROEs, signaling value dilution for shareholders. Continued deterioration likely necessitates further fundraising, increasing dilution risk and reducing shareholder claims on future upside absent marked improvement in profitability or financing terms.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.07 and its highest was AU$0.18 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$7.52M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 146 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Feb 12, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.72%
12-Months-Change
Fundamentals
Return on Equity
-17.07%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Technical Analysis
Alterity Therapeutics
―
AnteoTech Ltd
―
AdAlta Ltd.
―
Chimeric Therapeutics Ltd.
―
Recce Pharmaceuticals Ltd.
―